logo
Trump claimed autism rates are rising. Here are the facts

Trump claimed autism rates are rising. Here are the facts

Yahoo08-03-2025
1 in 36 eight-year-old children in the U.S. were identified as having an Autism Spectrum Disorder (ASD) diagnosis in 2020, according to the CDC. The prevalence of diagnoses has increased in recent decades, both in the U.S. and abroad.
Reasons for this rise include increased awareness, changes to how professionals diagnose and identify ASD, and increased community capacity, meaning the development of services in the community that might identify and support people with an ASD diagnosis.
According to the CDC, studies show that "vaccines are not associated with ASD." There is also no single cause of ASD.
Speaking to a joint session of Congress on March 4, 2025, U.S. President Donald Trump repeated a claim that autism rates among children are rising and that his pick to lead the nation's top health agency — Robert F. Kennedy Jr., or "Bobby" — was positioned to "figure out what is going on." Trump said:
As an example, not long ago — and you can't even believe these numbers — one in 10,000 children had autism. One in 10,000, and now it's one in 36. There's something wrong. One in 36. Think of that. So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you. You have the best to figure out what is going on.
It was not the first time Trump made the claim about autism rates and praised Kennedy, who has long promoted the debunked notion that vaccines cause autism, as being a solution to the alleged trend. Kennedy was sworn in as the leader of the Department of Health and Human Services on Feb. 13, 2025.
Trump's claim that autism diagnoses have increased is supported by research that shows a rise in autism prevalence (now called autism spectrum disorder, or ASD) in recent decades, both in the U.S. and globally. Prevalence in this case means the proportion of people in the population who have an ASD diagnosis at any given time.
However, the past figures Trump cited were lower than what research suggests.
On a page titled "Frequently Asked Questions about Autism Spectrum Disorder," the Centers for Disease Control and Prevention wrote that "the prevalence of ASD among 8-year-olds has increased most years since CDC began tracking ASD in 2000."
Autism has been part of the autism spectrum disorder group of diagnoses in "The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition" (DSM-5) since 2019. The DSM-5 is a taxonomic and diagnostic tool published by the American Psychiatric Association.
In terms of the other numbers given, Trump's "one in 36" figure likely stems from CDC figures in 2023 that looked at autism prevalence in 8-year-old children from select states who were part of the CDC's Autism and Developmental Disabilities Monitoring Network.
Separate data from the CDC's "Autism Prevalence Studies Data Table" shows that in the U.S. from 1992 to 1994 — approximately 30 years ago — autism prevalence, measured through parent reports, was 38 in 100,000 children under the age of 18 nationally — higher than Trump's December 2024 estimates. In other words, the research shows that autism rates have increased since the early 1990s, but not as much as Trump claimed.
Autism researchers point to various reasons to explain the increase in the prevalence of autism in the past few decades.
In a 2022 paper published in Autism Research, a journal published by the International Society for Autism Research, which promotes research into the disorder, researchers found: "An increase in measured autism prevalence globally, reflecting the combined effects of multiple factors including the increase in community awareness and public health response globally, progress in case identification and definition, and an increase in community capacity."
In an example of how increased community awareness could lead to a rise in diagnoses, researchers from Incite, a social science research institute at Columbia University, found in 2010 that children living near other children who received an autism diagnosis were more likely to receive one of their own.
According to the study's authors, this was due to interaction between parents and the resulting increase in awareness of the signs of autism in children.
Another factor that may have resulted in higher reports of ASD diagnoses was the design of surveys used to measure how many people had been diagnosed with the disorder. Researchers studying the 2014 National Health Interview Survey, a national survey that monitors the health of the U.S. population, found that in this particular survey, a change in methodology resulted in a rise in reported ASD diagnoses.
After surveyors switched the order of questions about ASD and developmental delays to asking about ASD first, ASD diagnoses were found to be higher than expected. Researchers concluded it was likely that, previously, "parents of children diagnosed with ASD reported this developmental disability as other DD [developmental disability] instead of, or in addition to, ASD."
Community capacity, or the ability of a community to detect and diagnose ASD in children, was also credited by researchers as a reason for the increased rise in diagnoses. Examples of this included initiatives such as the CDC's "Learn the Signs. Act Early" program, which helps parents or child care professionals react early if a child is not meeting developmental milestones.
The American Academy of Pediatrics now also recommends that children be screened for ASD at 18 and 24 months. Recommendations like these might help initiate ASD assessments that wouldn't have happened before.
The CDC's research shows that children are becoming more and more likely to be diagnosed early — in 2020, for example, researchers found that children who were 4 that year (that is, children born in 2016) were 1.6 times as likely to have been diagnosed with ASD as children who were 8 (those born in 2012).
Aside from societal and scientific changes to how professionals diagnose and track ASD, researchers also believe that an advanced parental age for both mothers and fathers may play a role in how likely a child is to be diagnosed with ASD.
A study of more than 5 million children from Denmark, Israel, Norway, Sweden and Western Australia found, among other results, that the older the parents were, the higher the "relative risk" of having a child with an ASD diagnosis.
Birth data from the U.S. showed that the average age of a first-time mother in 2022 was 27.4 years, up from 27.3 years in 2021. According to a report on the data published by the National Center for Health Statistics, which is part of the CDC, that data represented a "record high for the nation" in terms of maternal age at first childbirth.
According to the CDC, "studies continue to show that vaccines are not associated with ASD." On an informational page about the disorder, the CDC also noted that scientists do not believe there is a single cause of ASD, which instead appears to be the result of multiple different factors.
Snopes has previously written about autism, including whether Amish people are diagnosed with the disorder and how misleading research claimed to show links between autism and vaccines.
Autism Diagnostic Criteria: DSM-5 | Autism Speaks. https://www.autismspeaks.org/autism-diagnostic-criteria-dsm-5. Accessed 27 Dec. 2024.
Autism Spectrum Disorder. https://www.aap.org/en/patient-care/autism/. Accessed 27 Dec. 2024.
Bloomberg Television. "Donald Trump Press Conference | Part 1 | December 16, 2024." YouTube, 16 Dec. 2024, https://www.youtube.com/watch?v=ae6Ux26h5R0.
CDC. "About Autism Spectrum Disorder." Autism Spectrum Disorder (ASD), 25 Nov. 2024, https://www.cdc.gov/autism/about/index.html.
---. "About NHIS." National Health Interview Survey, 21 Nov. 2024, https://www.cdc.gov/nchs/nhis/about/index.html.
---. "Frequently Asked Questions about Autism Spectrum Disorder." Autism Spectrum Disorder (ASD), 5 Nov. 2024, https://www.cdc.gov/autism/faq/index.html.
---. "'Learn the Signs. Act Early.' Has FREE Child Development Tools." Centers for Disease Control and Prevention, 19 Nov. 2024, https://www.cdc.gov/ncbddd/actearly/index.html.
Centers for Disease Control and Prevention. CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network. Centers for Disease Control and Prevention, 2023, https://www.cdc.gov/autism/media/pdfs/2023-ADDM-Factsheet_508.pdf.
Fox News. "President-Elect Donald Trump Speaks at Turning Point's AmericaFest 2024." YouTube, 22 Dec. 2024, https://www.youtube.com/watch?v=Lo96y4mgak0.
Grosvenor, Luke P., et al. "Autism Diagnosis Among US Children and Adults, 2011-2022." JAMA Network Open, vol. 7, no. 10, Oct. 2024, p. e2442218. DOI.org (Crossref), https://doi.org/10.1001/jamanetworkopen.2024.42218.
Halfon, Neal, and Paul W. Newacheck. "Prevalence and Impact of Parent‐Reported Disabling Mental Health Conditions Among U.S. Children." Journal of the American Academy of Child & Adolescent Psychiatry, vol. 38, no. 5, May 1999, pp. 600–09. DOI.org (Crossref), https://doi.org/10.1097/00004583-199905000-00023.
Osterman, Michelle J. K., et al. "Births: Final Data for 2022." National Vital Statistics Reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, vol. 73, no. 2, Apr. 2024, pp. 1–56.
Sandin, S., et al. "Autism Risk Associated with Parental Age and with Increasing Difference in Age between the Parents." Molecular Psychiatry, vol. 21, no. 5, May 2016, pp. 693–700. PubMed, https://doi.org/10.1038/mp.2015.70.
"Social Influence and the Autism Epidemic." Incite at Columbia University, https://incite.columbia.edu/social-influence-and-the-autis. Accessed 27 Dec. 2024.
Zablotsky, Benjamin, et al. "Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey." National Health Statistics Reports, no. 87, Nov. 2015, pp. 1–20.
Zeidan, Jinan, et al. "Global Prevalence of Autism: A Systematic Review Update." Autism Research, vol. 15, no. 5, May 2022, pp. 778–90. DOI.org (Crossref), https://doi.org/10.1002/aur.2696.
"Read the Full Text of Trump's Speech to a Joint Session of Congress." PBS News, 5 Mar. 2025, https://www.pbs.org/newshour/politics/read-the-full-text-of-trumps-speech-to-a-joint-session-of-congress.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

Yahoo

time2 hours ago

  • Yahoo

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

Yahoo

time2 hours ago

  • Yahoo

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Yahoo

time3 hours ago

  • Yahoo

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store